Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "bundlepackageleaflet-en-16d693c68a441b92f0316a8bd5fd9c6e",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"
]
},
"language" : "en",
"identifier" : {
"system" : "http://ema.europa.eu/identifier",
"value" : "None"
},
"type" : "document",
"timestamp" : "2023-06-27T10:09:22Z",
"entry" : [
{
"fullUrl" : "Composition/composition-en-16d693c68a441b92f0316a8bd5fd9c6e",
"resource" : {
"resourceType" : "Composition",
"id" : "composition-en-16d693c68a441b92f0316a8bd5fd9c6e",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-16d693c68a441b92f0316a8bd5fd9c6e\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-16d693c68a441b92f0316a8bd5fd9c6e</b></p><a name=\"composition-en-16d693c68a441b92f0316a8bd5fd9c6e\"> </a><a name=\"hccomposition-en-16d693c68a441b92f0316a8bd5fd9c6e\"> </a><a name=\"composition-en-16d693c68a441b92f0316a8bd5fd9c6e-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/13/859/001-006</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - corbilta</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/13/859/001-006"
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package Leaflet"
},
"category" : [
{
"coding" : [
{
"system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
"code" : "R",
"display" : "Raw"
}
]
}
],
"subject" : [
{
"reference" : "MedicinalProductDefinition/mp16d693c68a441b92f0316a8bd5fd9c6e"
}
],
"date" : "2022-02-16T13:28:17Z",
"author" : [
{
🔗 "reference" : "Organization/mah-ema"
}
],
"title" : "TEST PURPOSES ONLY - corbilta",
"attester" : [
{
"mode" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/composition-attestation-mode",
"code" : "official"
}
]
},
"time" : "2022-02-16T13:28:17Z"
}
],
"section" : [
{
"title" : "B. Package Leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "B. Package Leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable"
}
]
},
"section" : [
{
"title" : "Package leaflet: Information for the user",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package leaflet: Information for the user"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
}
},
{
"title" : "What is in this leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "What is in this leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet:</p><ol type=\"1\"><li>What Corbilta is and what it is used for</li><li>What you need to know before you take Corbilta</li><li>How to take Corbilta</li><li>Possible side effects</li><li>How to store Corbilta</li><li>Contents of the pack and other information</li></ol></div>"
}
},
{
"title" : "1. What corbilta is and what it is used for",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "1. What corbilta is and what it is used for"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Corbilta contains three active substances (levodopa, carbidopa and entacapone) in one film-coated tablet. Corbilta is used for the treatment of Parkinson s disease. Parkinson s disease is caused by low levels of a substance called dopamine in the brain. Levodopa increases the amount of dopamine and hence reduces the symptoms of Parkinson s disease. Carbidopa and entacapone improve the antiparkinson effects of levodopa.</p></div>"
}
},
{
"title" : "2. What you need to know before you take corbilta",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "2. What you need to know before you take corbilta"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><h2 id=\"do-not-take-corbilta-if-you\">Do not take Corbilta if you:</h2><h2 id=\"are-allergic-to-levodopa-carbidopa-or-entacapone-or-any-of-the-other-ingredients-of-this-medicine-listed-in-section-6\">are allergic to levodopa, carbidopa or entacapone, or any of the other ingredients of this medicine (listed in section 6)</h2><h2 id=\"have-narrow-angle-glaucoma-an-eye-disorder\">have narrow-angle glaucoma (an eye disorder)</h2><h2 id=\"have-a-tumour-of-the-adrenal-gland\">have a tumour of the adrenal gland</h2><h2 id=\"are-taking-certain-medicines-for-treating-depression-combinations-of-selective-mao-a-and-mao-b-inhibitors-or-non-selective-mao-inhibitors\">are taking certain medicines for treating depression (combinations of selective MAO-A and MAO-B inhibitors, or non-selective MAO-inhibitors)</h2><h2 id=\"have-ever-had-neuroleptic-malignant-syndrome-nms-this-is-a-rare-reaction-to-medicines-used-to-treat-severe-mental-disorders\">have ever had neuroleptic malignant syndrome (NMS this is a rare reaction to medicines used to treat severe mental disorders)</h2><h2 id=\"have-ever-had-non-traumatic-rhabdomyolysis-a-rare-muscle-disorder\">have ever had non-traumatic rhabdomyolysis (a rare muscle disorder)</h2><h2 id=\"have-a-severe-liver-disease-warnings-and-precautions-talk-to-your-doctor-or-pharmacist-before-taking-corbilta-if-you-have-or-have-ever-had\">have a severe liver disease. Warnings and precautions Talk to your doctor or pharmacist before taking Corbilta if you have or have ever had:</h2><h2 id=\"a-heart-attack-or-any-other-diseases-of-the-heart-including-cardiac-arrhythmias-or-of-the-blood-vessels\">a heart attack or any other diseases of the heart including cardiac arrhythmias, or of the blood vessels</h2><h2 id=\"asthma-or-any-other-disease-of-the-lungs\">asthma or any other disease of the lungs</h2><h2 id=\"a-liver-problem-because-your-dose-may-need-to-be-adjusted\">a liver problem, because your dose may need to be adjusted</h2><h2 id=\"kidney-or-hormone-related-diseases\">kidney or hormone-related diseases</h2><h2 id=\"stomach-ulcers-or-convulsions\">stomach ulcers or convulsions</h2><h2 id=\"if-you-experience-prolonged-diarrhoea-consult-your-doctor-as-it-may-be-a-sign-of-inflammation-of-the-colon\">if you experience prolonged diarrhoea consult your doctor as it may be a sign of inflammation of the colon</h2><h2 id=\"any-form-of-severe-mental-disorder-like-psychosis\">any form of severe mental disorder like psychosis</h2><h2 id=\"chronic-wide-angle-glaucoma-because-your-dose-may-need-to-be-adjusted-and-the-pressure-in-your-eyes-may-need-to-be-monitored-consult-your-doctor-if-you-are-currently-taking\">chronic wide-angle glaucoma, because your dose may need to be adjusted and the pressure in your eyes may need to be monitored. Consult your doctor if you are currently taking:</h2><h2 id=\"antipsychotics-medicines-used-to-treat-psychosis\">antipsychotics (medicines used to treat psychosis)</h2><h2 id=\"a-medicine-which-may-cause-low-blood-pressure-when-rising-from-a-chair-or-bed-you-should-be-aware-that-corbilta-may-make-these-reactions-worse-consult-your-doctor-if-during-the-treatment-with-corbilta-you\">a medicine which may cause low blood pressure when rising from a chair or bed. You should be aware that Corbilta may make these reactions worse. Consult your doctor if during the treatment with Corbilta you:</h2><h2 id=\"notice-that-your-muscles-get-very-rigid-or-jerk-violently-or-if-you-get-tremors-agitation-confusion-fever-rapid-pulse-or-wide-fluctuations-in-your-blood-pressure-if-any-of-this-happens-contact-your-doctor-immediately\">notice that your muscles get very rigid or jerk violently, or if you get tremors, agitation, confusion, fever, rapid pulse, or wide fluctuations in your blood pressure. If any of this happens, contact your doctor immediately.</h2><h2 id=\"feel-depressed-have-suicidal-thoughts-or-notice-unusual-changes-in-your-behaviour\">feel depressed, have suicidal thoughts, or notice unusual changes in your behaviour</h2><h2 id=\"find-yourself-suddenly-falling-asleep-or-if-you-feel-very-drowsy-if-this-happens-you-should-not-drive-or-use-any-tools-or-machines-see-also-section-driving-and-using-machines-\">find yourself suddenly falling asleep, or if you feel very drowsy. If this happens, you should not drive or use any tools or machines (see also section Driving and using machines ).</h2><h2 id=\"notice-that-uncontrolled-movements-begin-or-get-worse-after-you-started-to-take-corbilta-if-this-happens-your-doctor-may-need-to-change-the-dose-of-your-antiparkinson-medicine\">notice that uncontrolled movements begin or get worse after you started to take Corbilta. If this happens, your doctor may need to change the dose of your antiparkinson medicine.</h2><h2 id=\"experience-diarrhoea-monitoring-of-your-weight-is-recommended-in-order-to-avoid-potentially-excessive-weight-loss\">experience diarrhoea: monitoring of your weight is recommended in order to avoid potentially excessive weight loss</h2><h2 id=\"experience-progressive-anorexia-asthenia-weakness-exhaustion-and-weight-decrease-within-a-relatively-short-period-of-time-if-this-happens-a-general-medical-evaluation-including-liver-function-should-be-considered\">experience progressive anorexia, asthenia (weakness, exhaustion) and weight decrease within a relatively short period of time. If this happens, a general medical evaluation including liver function should be considered.</h2><h2 id=\"feel-the-need-to-stop-using-corbilta-see-section-if-you-stop-taking-corbilta--tell-your-doctor-if-you-or-your-familycarer-notices-you-are-developing-addiction-like-symptoms-leading-to-craving-for-large-doses-of-corbilta-and-other-medicines-used-to-treat-parkinson-s-disease-tell-your-doctor-if-you-or-your-familycarer-notices-you-are-developing-urges-or-cravings-to-behave-in-ways-that-are-unusual-for-you-or-you-cannot-resist-the-impulse-drive-or-temptation-to-carry-out-certain-activities-that-could-harm-yourself-or-others-these-behaviours-are-called-impulse-control-disorders-and-can-include-addictive-gambling-excessive-eating-or-spending-an-abnormally-high-sex-drive-or-a-preoccupation-with-an-increase-in-sexual-thoughts-or-feelings-your-doctor-may-need-to-review-your-treatments-your-doctor-may-take-some-regular-laboratory-tests-during-a-long-term-treatment-with-corbilta-if-you-must-undergo-surgery-please-tell-your-doctor-that-you-are-using-corbilta-corbilta-is-not-recommended-to-be-used-for-treatment-of-extrapyramidal-symptoms-eg-involuntary-movements-shaking-muscle-rigidity-and-muscle-contractions-caused-by-other-medicines-children-and-adolescents-experience-with-corbilta-in-patients-under-18-years-is-limited-therefore-the-use-of-corbilta-in-children-or-adolescents-is-not-recommended-other-medicines-and-corbilta-tell-your-doctor-or-pharmacist-if-you-are-taking-have-recently-taken-or-might-take-any-other-medicines-do-not-take-corbilta-if-you-are-taking-certain-medicines-for-treating-depression-combinations-of-selective-mao-a-and-mao-b-inhibitors-or-non-selective-mao-inhibitors-corbilta-may-increase-the-effects-and-side-effects-of-certain-medicines-these-include\">feel the need to stop using Corbilta, see section If you stop taking Corbilta . Tell your doctor if you or your family/carer notices you are developing addiction-like symptoms leading to craving for large doses of Corbilta and other medicines used to treat Parkinson s disease. Tell your doctor if you or your family/carer notices you are developing urges or cravings to behave in ways that are unusual for you or you cannot resist the impulse, drive or temptation to carry out certain activities that could harm yourself or others. These behaviours are called impulse control disorders and can include addictive gambling, excessive eating or spending, an abnormally high sex drive or a preoccupation with an increase in sexual thoughts or feelings. Your doctor may need to review your treatments. Your doctor may take some regular laboratory tests during a long term treatment with Corbilta. If you must undergo surgery, please tell your doctor that you are using Corbilta. Corbilta is not recommended to be used for treatment of extrapyramidal symptoms (e.g. involuntary movements, shaking, muscle rigidity and muscle contractions) caused by other medicines. Children and adolescents Experience with Corbilta in patients under 18 years is limited. Therefore, the use of Corbilta in children or adolescents is not recommended. Other medicines and Corbilta Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Do not take Corbilta if you are taking certain medicines for treating depression (combinations of selective MAO-A and MAO-B inhibitors, or non-selective MAO inhibitors). Corbilta may increase the effects and side effects of certain medicines. These include:</h2><h2 id=\"medicines-used-to-treat-depression-such-as-moclobemide-amitriptyline-desipramine-maprotiline-venlafaxine-and-paroxetine\">medicines used to treat depression such as moclobemide, amitriptyline, desipramine, maprotiline, venlafaxine and paroxetine</h2><h2 id=\"rimiterole-and-isoprenaline-used-to-treat-respiratory-diseases\">rimiterole and isoprenaline, used to treat respiratory diseases</h2><h2 id=\"adrenaline-used-for-severe-allergic-reactions\">adrenaline, used for severe allergic reactions</h2><h2 id=\"noradrenaline-dopamine-and-dobutamine-used-to-treat-heart-diseases-and-low-blood-pressure\">noradrenaline, dopamine and dobutamine, used to treat heart diseases and low blood pressure</h2><h2 id=\"alpha-methyldopa-used-to-treat-high-blood-pressure\">alpha-methyldopa, used to treat high blood pressure</h2><h2 id=\"apomorphine-which-is-used-to-treat-parkinson-s-disease-the-effects-of-corbilta-may-be-weakened-by-certain-medicines-these-include\">apomorphine, which is used to treat Parkinson s disease. The effects of Corbilta may be weakened by certain medicines. These include:</h2><h2 id=\"dopamine-antagonists-used-to-treat-mental-disorders-nausea-and-vomiting\">dopamine antagonists used to treat mental disorders, nausea and vomiting</h2><h2 id=\"phenytoin-used-to-prevent-convulsions\">phenytoin, used to prevent convulsions</h2><p>papaverine used to relax the muscles. Corbilta may make it harder for you to digest iron. Therefore, do not take Corbilta and iron supplements at the same time. After taking one of them, wait at least 2 to 3 hours before taking the other. Corbilta with food and drink Corbilta may be taken with or without food. For some patients, Corbilta may not be well absorbed if it is taken with, or shortly after eating protein-rich food (such as meats, fish, dairy products, seeds and nuts). Consult your doctor if you think this applies to you. Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You should not breast-feed during treatment with Corbilta. Driving and using machines Corbilta may lower your blood pressure, which may make you feel light-headed or dizzy. Therefore, be particularly careful when you drive or when you use any tools or machines. If you feel very drowsy, or if you sometimes find yourself suddenly falling asleep, wait until you feel fully awake again before driving or doing anything else that requires you to be alert. Otherwise, you may put yourself and others at risk of serious injury or death. Corbilta contains sucrose Corbilta contains sucrose (1.2 mg/tablet). If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicine. This medicine contains less than 1 mmol (23 mg) sodium per maximum recommended daily dose, that is to say essentially sodium-free .</p></div>"
}
},
{
"title" : "3. How to take corbilta",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "3. How to take corbilta"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><h2 id=\"always-take-this-medicine-exactly-as-your-doctor-or-pharmacist-has-told-you-check-with-your-doctor-or-pharmacist-if-you-are-not-sure-for-adults-and-elderly\">Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. For adults and elderly:</h2><h2 id=\"your-doctor-will-tell-you-exactly-how-many-tablets-of-corbilta-to-take-each-day\">Your doctor will tell you exactly how many tablets of Corbilta to take each day.</h2><h2 id=\"the-tablets-are-not-intended-to-be-split-or-broken-into-smaller-pieces\">The tablets are not intended to be split or broken into smaller pieces.</h2><h2 id=\"you-should-take-only-one-tablet-each-time\">You should take only one tablet each time.</h2><h2 id=\"depending-on-how-you-respond-to-treatment-your-doctor-may-suggest-a-higher-or-lower-dose\">Depending on how you respond to treatment, your doctor may suggest a higher or lower dose.</h2><p>If you are taking Corbilta 50 mg/12.5 mg/200 mg, 75 mg/18.75 mg/200 mg, 100 mg/25 mg/200 mg, 125 mg/31.25 mg/200 mg or 150 mg/37.5 mg/200 mg tablets, do not take more than 10 tablets per day. Talk to your doctor or pharmacist if you think the effect of Corbilta is too strong or too weak, or if you experience possible side effects. To open the bottle for the first time: open the closure, and then press with your thumb on the seal until it breaks. See picture 1. Picture 1 If you take more Corbilta than you should If you have accidentally taken more Corbilta tablets than you should, talk to your doctor or pharmacist immediately. In case of an overdose you may feel confused or agitated, your heart rate may be slower or faster than normal or the colour of your skin, tongue, eyes or urine may change. If you forget to take Corbilta Do not take a double dose to make up for a forgotten tablet. If it is more than 1 hour until your next dose: Take one tablet as soon as you remember, and the next tablet at the normal time. If it is less than 1 hour until your next dose: Take a tablet as soon as you remember, wait 1 hour, then take another tablet. After that carry on as normal. Always leave at least an hour between Corbilta tablets, to avoid possible side effects. If you stop taking Corbilta Do not stop taking Corbilta unless your doctor tells you to. In such a case your doctor may need to adjust your other antiparkinson medicines, especially levodopa, to give sufficient control of your symptoms. If you suddenly stop taking Corbilta and other antiparkinsonian medicines it may result in unwanted side effects. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>"
}
},
{
"title" : "4. Possible side effects",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "4. Possible side effects"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><h2 id=\"like-all-medicines-this-medicine-can-cause-side-effects-although-not-everybody-gets-them-many-of-the-side-effects-can-be-relieved-by-adjusting-the-dose-if-you-during-the-treatment-with-corbilta-experience-the-following-symptoms-contact-your-doctor-immediately\">Like all medicines, this medicine can cause side effects, although not everybody gets them. Many of the side effects can be relieved by adjusting the dose. If you during the treatment with Corbilta experience the following symptoms, contact your doctor immediately:</h2><h2 id=\"your-muscles-get-very-rigid-or-jerk-violently-you-get-tremors-agitation-confusion-fever-rapid-pulse-or-wide-fluctuations-in-your-blood-pressure-these-can-be-symptoms-of-neuroleptic-malignant-syndrome-nms-a-rare-severe-reaction-to-medicines-used-to-treat-disorders-of-the-central-nervous-system-or-rhabdomyolysis-a-rare-severe-muscle-disorder\">Your muscles get very rigid or jerk violently, you get tremors, agitation, confusion, fever, rapid pulse, or wide fluctuations in your blood pressure. These can be symptoms of neuroleptic malignant syndrome (NMS, a rare severe reaction to medicines used to treat disorders of the central nervous system) or rhabdomyolysis (a rare severe muscle disorder).</h2><h2 id=\"allergic-reaction-the-signs-may-include-hives-nettle-rash-itching-rash-swelling-of-your-face-lips-tongue-or-throat-this-may-cause-difficulties-in-breathing-or-swallowing-very-common-may-affect-more-than-1-in-10-people\">Allergic reaction, the signs may include hives (nettle rash), itching, rash, swelling of your face, lips, tongue or throat. This may cause difficulties in breathing or swallowing. Very common (may affect more than 1 in 10 people):</h2><h2 id=\"uncontrolled-movements-dyskinesias\">uncontrolled movements (dyskinesias)</h2><h2 id=\"feeling-sick-nausea\">feeling sick (nausea)</h2><h2 id=\"harmless-reddish-brown-discolouration-of-urine\">harmless reddish-brown discolouration of urine</h2><h2 id=\"muscle-pain\">muscle pain</h2><h2 id=\"diarrhoea-common-may-affect-up-to-1-in-10-people\">diarrhoea. Common (may affect up to 1 in 10 people):</h2><h2 id=\"light-headedness-or-fainting-due-to-low-blood-pressure-high-blood-pressure\">light-headedness or fainting due to low blood pressure, high blood pressure</h2><h2 id=\"worsening-of-parkinsons-symptoms-dizziness-drowsiness\">worsening of Parkinson`s symptoms, dizziness, drowsiness</h2><h2 id=\"vomiting-abdominal-pain-and-discomfort-heartburn-dry-mouth-constipation\">vomiting, abdominal pain and discomfort, heartburn, dry mouth, constipation</h2><h2 id=\"inability-to-sleep-hallucinations-confusion-abnormal-dreams-including-nightmares-tiredness\">inability to sleep, hallucinations, confusion, abnormal dreams (including nightmares), tiredness</h2><h2 id=\"mental-changes-including-problems-with-memory-anxiety-and-depression-possibly-with-thoughts-of-suicide\">mental changes including problems with memory, anxiety and depression (possibly with thoughts of suicide)</h2><h2 id=\"heart-or-artery-disease-events-eg-chest-pain-irregular-heart-rate-or-rhythm\">heart or artery disease events (e.g. chest pain), irregular heart rate or rhythm</h2><h2 id=\"more-frequent-falling\">more frequent falling</h2><h2 id=\"shortness-of-breath\">shortness of breath</h2><h2 id=\"increased-sweating-rashes\">increased sweating, rashes</h2><h2 id=\"muscle-cramps-swelling-of-legs\">muscle cramps, swelling of legs</h2><h2 id=\"blurred-vision\">blurred vision</h2><h2 id=\"anaemia\">anaemia</h2><h2 id=\"decreased-appetite-decreased-weight\">decreased appetite, decreased weight</h2><h2 id=\"headache-joint-pain\">headache, joint pain</h2><h2 id=\"urinary-tract-infection-uncommon-may-affect-up-to-1-in-100-people\">urinary tract infection. Uncommon (may affect up to 1 in 100 people):</h2><h2 id=\"heart-attack\">heart attack</h2><h2 id=\"bleeding-in-the-gut\">bleeding in the gut</h2><h2 id=\"changes-in-the-blood-cell-count-which-may-result-in-bleeding-abnormal-liver-function-tests\">changes in the blood cell count which may result in bleeding, abnormal liver function tests</h2><h2 id=\"convulsions\">convulsions</h2><h2 id=\"feeling-agitated\">feeling agitated</h2><h2 id=\"psychotic-symptoms\">psychotic symptoms</h2><h2 id=\"colitis-inflammation-of-the-colon\">colitis (inflammation of the colon)</h2><h2 id=\"discolourations-other-than-urine-eg-skin-nail-hair-sweat\">discolourations other than urine (e.g. skin, nail, hair, sweat)</h2><h2 id=\"swallowing-difficulties\">swallowing difficulties</h2><h2 id=\"inability-to-urinate-not-known-frequency-cannot-be-estimated-from-the-available-data-craving-for-large-doses-of-corbilta-in-excess-of-that-required-to-control-motor-symptoms-known-as-dopamine-dysregulation-syndrome-some-patients-experience-severe-abnormal-involuntary-movements-dyskinesias-mood-swings-or-other-side-effects-after-taking-large-doses-of-corbilta-the-following-side-effects-have-also-been-reported\">inability to urinate. Not known (frequency cannot be estimated from the available data): Craving for large doses of Corbilta in excess of that required to control motor symptoms, known as dopamine dysregulation syndrome. Some patients experience severe abnormal involuntary movements (dyskinesias), mood swings or other side effects after taking large doses of Corbilta. The following side effects have also been reported:</h2><h2 id=\"hepatitis-inflammation-of-the-liver\">hepatitis (inflammation of the liver)</h2><h2 id=\"itching-you-may-experience-the-following-side-effects\">itching. You may experience the following side effects:</h2><h2 id=\"inability-to-resist-the-impulse-to-perform-an-action-that-could-be-harmful-which-may-include\">Inability to resist the impulse to perform an action that could be harmful, which may include:</h2><h2 id=\"strong-impulse-to-gamble-excessively-despite-serious-personal-or-family-consequences\">strong impulse to gamble excessively despite serious personal or family consequences</h2><h2 id=\"altered-or-increased-sexual-interest-and-behaviour-of-significant-concern-to-you-or-to-others-for-example-an-increased-sexual-drive\">altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive</h2><h2 id=\"uncontrollable-excessive-shopping-or-spending\">uncontrollable excessive shopping or spending</h2><p>binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger). Tell your doctor if you experience any of these behaviours; they will discuss ways of managing or reducing the symptoms. Reporting of side effects If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>"
}
},
{
"title" : "5. How to store corbilta",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "5. How to store corbilta"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the bottle and the carton. The expiry date refers to the last day of that month. This medicinal product does not require any special storage conditions. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p></div>"
}
},
{
"title" : "6. Contents of the pack and other information",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "6. Contents of the pack and other information"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><h2 id=\"what-corbilta-contains\">What Corbilta contains</h2><h2 id=\"the-active-substances-of-corbilta-are-levodopa-carbidopa-and-entacapone\">The active substances of Corbilta are levodopa, carbidopa and entacapone.</h2><h2 id=\"each-corbilta-50-mg125-mg200-mg-tablet-contains-50-mg-of-levodopa-125-mg-of-carbidopa-and-200-mg-of-entacapone\">Each Corbilta 50 mg/12.5 mg/200 mg tablet contains 50 mg of levodopa, 12.5 mg of carbidopa and 200 mg of entacapone.</h2><h2 id=\"the-other-ingredients-in-the-tablet-core-are-croscarmellose-sodium-magnesium-stearate-maize-starch-mannitol-e421-and-povidone-e1201\">The other ingredients in the tablet core are croscarmellose sodium, magnesium stearate, maize starch, mannitol (E421) and povidone (E1201).</h2><p>The ingredients in the film-coating are glycerol (85 per cent) (E422), hypromellose, magnesium stearate, polysorbate 80, red iron oxide (E172), sucrose, titanium dioxide (E171), and yellow iron oxide (E172). What Corbilta looks like and contents of the pack Corbilta 50 mg/12.5 mg/200 mg: brownish or greyish red, round, convex unscored film-coated tablets marked with LCE 50 on one side. Corbilta comes in six different pack sizes (10, 30, 100, 130, 175 or 250 tablets). Not all pack sizes may be marketed. Marketing Authorisation Holder Orion Corporation Orionintie 1 FI-02200 Espoo Finland Manufacturer Orion Corporation Orion Pharma Joensuunkatu 7 FI-24100 Salo Finland For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder. Belgi /Belgique/Belgien Sandoz n.v./s.a. T l/Tel: +32 2 722 97 Lietuva Orion Corporation Tel. +358 10 4</p><p>Te .: + 359 2 970 47 Luxembourg/Luxemburg Sandoz n.v./s.a. T l/Tel: +32 2 722 97 esk republika Sandoz s.r.o. Tel: +420 225 775 Magyarorsz g Sandoz Hung ria Kft. Tel.: +36 1 430 2Danmark Orion Corporation Tlf: +358 10 4Malta Orion Corporation Tel: +358 10 4Deutschland Orion Corporation Tel: +358 10 4Nederland Sandoz B.V. Tel: +31 (0)36 5241Eesti Orion Corporation Tel: +358 10 4Norge Orion Corporation Tlf: +358 10 4 Novartis (Hellas) S.A.C.I. : +30 210 2811 sterreich Sandoz GmbH Tel: +43 5338 200 0 Espa a Orion Corporation Tel: +358 10 4Polska Orion Corporation Tel.: +358 10 4France Orion Corporation T l: +358 10 4Portugal Sandoz Farmac utica Lda. Tel: +351 21 924 19 Hrvatska Sandoz d.o.o. Tel. +385 1 2353 Rom nia S.C Sandoz S.R.L. +40 21 407 51 Ireland Orion Corporation Tel: +358 10 4Slovenija Lek Pharmaceuticals d.d. Tel: +386 1 580 21 sland Orion Corporation S mi: +358 10 4Slovensk republika Sandoz d.d. organiza n zlo ka Tel: +421 2 48 200 Italia Sandoz S.p.A. Tel: +39 02 96 54 3Suomi/Finland Orion Corporation Puh./Tel: +358 10 4 Sandoz GmbH : +43 5338 200 0 Sverige Orion Corporation Tel: +358 10 4Latvija Orion Corporation Tel: +358 10 4United Kingdom (Northern Ireland) Orion Corporation Tel: +358 10 4This leaflet was last revised in. Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>"
}
}
]
}
]
}
},
{
"fullUrl" : "MedicinalProductDefinition/mp16d693c68a441b92f0316a8bd5fd9c6e",
"resource" : {
"resourceType" : "MedicinalProductDefinition",
"id" : "mp16d693c68a441b92f0316a8bd5fd9c6e",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mp16d693c68a441b92f0316a8bd5fd9c6e\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mp16d693c68a441b92f0316a8bd5fd9c6e</b></p><a name=\"mp16d693c68a441b92f0316a8bd5fd9c6e\"> </a><a name=\"hcmp16d693c68a441b92f0316a8bd5fd9c6e\"> </a><a name=\"mp16d693c68a441b92f0316a8bd5fd9c6e-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/13/859/001-006</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Corbilta 50 mg/12.5 mg/200 mg film-coated tablets</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/13/859/001-006"
}
],
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-type",
"code" : "MedicinalProduct",
"display" : "Medicinal Product"
}
]
},
"domain" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-domain",
"code" : "Human",
"display" : "Human use"
}
]
},
"status" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/publication-status",
"code" : "active",
"display" : "active"
}
]
},
"legalStatusOfSupply" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi",
"code" : "100000072084",
"display" : "Medicinal product subject to medical prescription"
}
]
},
"name" : [
{
"productName" : "Corbilta 50 mg/12.5 mg/200 mg film-coated tablets",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000001",
"display" : "Full name"
}
]
},
"part" : [
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000002",
"display" : "Invented name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000003",
"display" : "Scientific name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000004",
"display" : "Strength part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000005",
"display" : "Pharmaceutical dose form part"
}
]
}
}
],
"usage" : [
{
"country" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"jurisdiction" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "en"
}
]
}
}
]
}
]
}
}
]
}
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
